MYGN Myriad Genetics Inc
XNAS
5.75
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
MYGN
$5.75
—
What changed
Recent filings, trades and movesKey stats
$5.75
- 52-Week Range
- $2.74 – $8.09
- YTD
- -6.27%
- IV Rank (30D)
- 37.78
- Straddle Price
- $2.12
- P/C Vol Ratio
- 0.20
- Market Cap
- $0.6B
- Open
- $5.92
- Day Range
- $5.63 – $5.92
- Volume
- 1,171,293
- Prev Close
- $5.92
Fair Value
+50.0% vs price
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.90% |
| Beta vs SPY | 1.36 |
| Cost of Equity (CAPM) | 12.36% (VRP-adj) |
| WACC | 11.10% |
| Volatility Risk Premium | +41.2pp (IV − HV30), ERP adj +50bps |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | -7.3% |
| DCF Horizon | 10 years explicit + fade |
| Free Cash Flow (TTM) | $-0.0B |
| Return on Equity (TTM) | -37.0% |
| Book / Price | 54.2% — banking bias active (P/B is primary) |
| Gross Margin (TTM) | 68.8% |
| FCF Margin (TTM) | -0.9% |
| Debt / Equity | 0.40 |
| Quality Score | 2/6 — normal (10y DCF) |
| SMA 50 | $4.50 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $5.49 |
| Bollinger Width / SMA20 | 66.7% (drives anchor stability) |
| Net Debt | $0.0B |
| Market Cap | $1B |
Peers used for multiples: BMRA, CLDX, NEOG, NTLA, QDEL
(SIC-code peers; ETF co-membership was sector-incoherent)
Blended Fair Value
$15.51
Deviation
+50.0%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | |
| Peer EV/EBITDA | n/a | 0% | |
| Peer P/B | $6.51 | 50% | median 2.0× · 5 peers |
| Peer P/S | $24.50 | 50% | median 2.9× · 5 peers |
| Market Anchor (SMA50) | $4.50 | 0% | stability 0% (BB-width) |
| Options Expected (B-L 30d) | $5.53 | 0% | 6 strikes · skew -0.38 |
As of 2026-11-09 · updated
Related
About
- Industry (SIC)
- IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES (2835) · industry map
- Exchange
- XNAS
- Market Cap
- $0.6B
- Employees
- 2,700
- List Date
- 1995-10-06
- CIK
- 0000899923
- Last Earnings
- Nov 4 after close · +4.5% vs ±20.8% expected
- Next Earnings
- ~Feb 22, 2027 (estimated)
- Headquarters
- Salt Lake City, UT
- Homepage
- https://www.myriad.com
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer r…
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | 38.30% | -6.14% | 29.23% | 12.58% | -6.15% | -8.47% | 9.89% |
| Feb | 6.96% | -6.09% | -5.12% | -3.15% | -15.97% | -15.72% | -6.52% |
| Mar | -1.33% | 7.23% | 8.45% | -3.88% | -14.63% | -10.18% | -2.39% |
| Apr | -3.17% | -20.79% | -10.40% | -8.72% | -16.18% | 3.49% | -9.29% |
| May | -5.76% | -9.20% | 1.66% | 16.90% | -41.23% | -17.29% | -9.15% |
| Jun | 9.21% | -4.67% | 0.35% | 9.44% | 19.06% | 33.41% | 11.13% |
| Jul | 1.02% | 41.60% | -3.75% | 16.69% | -30.56% | -52.21% | -4.53% |
| Aug | 15.94% | -14.04% | -18.01% | 2.64% | 62.92% | 6.62% | 9.35% |
| Sep | -11.92% | -14.78% | -10.99% | -0.25% | 4.78% | 35.53% | 0.40% |
| Oct | -3.51% | 5.92% | 0.45% | -18.76% | 4.01% | 56.40% | 7.42% |
| Nov | -17.09% | 15.77% | 21.28% | -9.56% | -6.72% | -1.45%* | 0.37% |
| Dec | 10.84% | -28.66% | -0.47% | -17.86% | -12.89% | -- | -9.81% |
| Total | 33.06% | -41.20% | 3.52% | -11.76% | -60.44% | -15.78% | -15.43% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $5.56
SMA 50: $4.55
SMA 200: $4.61
Current: $5.74
EMA 12: $5.89
EMA 26: $5.43
MACD: 0.4597 | Signal: -0.0576
BULLISH
ADX (14): 48.22
STRONG TREND
+DI: 36.44
−DI: 18.19
Momentum Oscillators
RSI (14): 55.69
NEUTRAL
Stoch %K: 50.81
Stoch %D: 64.82
Williams %R: -74.63
Volume & Volatility
BB Upper: $7.30
BB Lower: $3.83
NEUTRAL
OBV: 27,724,829
Vol SMA 20: 3,238,548
Vol ROC: -22.84%
ATR: $0.39
True Range: $0.29
HV 20: 120.1%
HV 30: 107.6%
HV 60: 86.7%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-11-08T00:00:00 – 2026-11-06T00:00:00
AI Analysis
Click Frenzy-Pro™ for an AI analysis of this ticker.
Analysis includes technical indicators, news sentiment, risk assessment, and specific price levels to watch.
News
All MYGN news →
Myriad is selling its Prenatal Health unit to Labcorp for $210 million in cash.
Earnings History
18 of 24 under expected move
Avg Expected Move
16.62%
Avg Actual Move
10.99%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2021-02-23 | After-Close | 19.46% | 3.69% | 0.19x | Within |
| 2021-05-03 | After-Close | 16.45% | 4.01% | 0.24x | Within |
| 2021-08-03 | After-Close | 13.62% | 1.19% | 0.09x | Within |
| 2021-11-02 | After-Close | 4.87% | 4.94% | 1.01x | Exceeded |
| 2022-01-11 | After-Close | 5.84% | 1.58% | 0.27x | Within |
| 2022-05-05 | After-Close | 7.40% | 0.60% | 0.08x | Within |
| 2022-11-01 | After-Close | 12.91% | 6.86% | 0.53x | Within |
| 2023-02-28 | After-Close | 12.95% | 13.21% | 1.02x | Exceeded |
| 2023-05-03 | After-Close | 13.43% | 3.65% | 0.27x | Within |
| 2023-08-03 | After-Close | 10.26% | 6.98% | 0.68x | Within |
| 2023-11-06 | After-Close | 13.95% | 8.69% | 0.62x | Within |
| 2024-01-16 | After-Close | 5.10% | 2.67% | 0.52x | Within |
| 2024-05-07 | After-Close | 11.38% | 21.08% | 1.85x | Exceeded |
| 2024-08-06 | After-Close | 13.67% | 2.62% | 0.19x | Within |
| 2024-10-09 | After-Close | 7.18% | 5.33% | 0.74x | Within |
| 2024-11-07 | After-Close | 10.33% | 1.47% | 0.14x | Within |
| 2025-02-24 | After-Close | 20.32% | 14.80% | 0.73x | Within |
| 2025-05-06 | After-Close | 19.94% | 41.27% | 2.07x | Exceeded |
| 2025-08-05 | After-Close | 41.34% | 46.51% | 1.13x | Exceeded |
| 2025-11-04 | After-Close | 27.09% | 1.86% | 0.07x | Within |
| 2026-02-23 | After-Close | 42.81% | 1.14% | 0.03x | Within |
| 2026-05-05 | After-Close | 25.84% | 18.29% | 0.71x | Within |
| 2026-07-30 | After-Close | 21.88% | 46.74% | 2.14x | Exceeded |
| 2026-11-04 | After-Close | 20.76% | 4.49% | 0.22x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
MYGN Options Activity & IV Rank
MYGN IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 109.7%
7-DTE IV: 99.9%
Expected Move: $2.12
7-DTE Move: $0.82
Days to Exp: 39 (2026-12-18)
Options Flow · All expiries
Call Volume: 838
Put Volume: 167
P/C Volume: 0.199
BULLISH
Call OI: 4,646
Put OI: 986
P/C OI: 0.212
Total OI: 5,632
ATM Options Pricing
ATM Call: $1.05
ATM Put: $1.07
Call %: 18.2%
Put %: 18.7%
Chain Summary
Chain Volume: 1,005
Chain OI: 5,632
Last Updated: 11/9/2026
Spread Scanner
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Scanning bull put, bear call, iron condor and calendar spreads…
Dealer Positioning
TYPICAL γ
Estimated net dealer gamma is at the 48th percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
48%
vs own history
GEX tilt
+0.65
OI-weighted, today
Vanna tilt
-0.14
δ-sensitivity to IV
Charm tilt
-0.48
δ-decay vs time
Charm tilt -0.48: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 8 ATM contracts, 3k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
No data
30 DTE / 10d
—
—
pts
EXTREME
No data
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Loading the implied volatility surface…
Volatility Smile
Loading the implied volatility smile…
IV Rank (7 DTE)12.9LowNov 9
IV Rank (30 DTE)37.8MediumNov 9
Straddle Price (30 DTE)$2.12Nov 9
Beta Analysis
Risk Metrics
Beta: 0.7577
Alpha: 21.70%
Correlation: 0.1234
R-Squared: 1.5%
Stock Volatility: 84.5%
Market Volatility: 13.8%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
Low volatility - stock moves less than market
Low volatility - stock moves less than market
Beta & Alpha Over Time
Notable investors who own MYGN
4 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Millennium Management Hedge fund Izzy Englander | $37.8M | #757 of 3716 | -0.7% | 13F | |
| Citadel Hedge fund Ken Griffin | $8.8M | #1686 of 6285 | +238.5% | 13F | |
| Point72 Hedge fund Steve Cohen | $1.4M | #1393 of 1945 | -75.1% | 13F | |
| Rockefeller Capital Management Family office Rockefeller family | $5K | #4253 of 4729 | -73.2% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
MYGN Institutional Ownership (13F)
Filings for 2026-06-30 · 55 already for 2026-09-30
? 13F Guide
Diluted shares outstanding: 93,550,000 (as of 2026-06-30)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
4 filers$257.26K notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Citadel Advisors LLC Custodian | $184.43K | 71.69% | 2026-06-30 |
| 2 | Walleye Capital LLC | $59.95K | 23.30% | 2026-06-30 |
| 3 | GROUP ONE TRADING LLC Custodian | $8.56K | 3.33% | 2026-06-30 |
| 4 | Simplex Trading, LLC Custodian | $4.31K | 1.67% | 2026-09-30 |
2 filers$118.20K notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Citadel Advisors LLC Custodian | $114.20K | 96.62% | 2026-06-30 |
| 2 | Walleye Capital LLC | $4.00K | 3.38% | 2026-06-30 |
MYGN Insider Trading (Form 4)
Latest: 2026-11-02Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-11-02 | Jennifer Lynne Fox | Chief Legal & Corp Strategy | Award (A) | +39,370 | — | EDGAR | |
| 2026-09-22 | Benjamin Richard Wheeler | Chief Financial Officer | Tax (F) | −2,555 | $4.01 | -$10.2K | EDGAR |
| 2026-09-18 | Brian J Donnelly | Chief Commercial Officer | — | — | — | EDGAR | |
| 2026-09-17 | Vishal Sikri | EVP, Commercial | Award (A) | +257,731 | — | EDGAR | |
| 2026-09-08 | Jennifer Lynne Fox | Chief Legal Officer | Tax (F) | −4,398 | $3.23 | -$14.2K | EDGAR |
| 2026-08-17 | Benjamin Richard Wheeler | Chief Financial Officer | Tax (F) | −8,761 | $3.03 | -$26.5K | EDGAR |
| 2026-06-23 | Daniel Skovronsky | Director | — | — | — | EDGAR | |
| 2026-06-12 | Brian J Donnelly | Chief Commerical Officer | Award (A) | +5,000 | $3.94 | $19.7K | EDGAR |
| 2026-06-12 | Samraat S. Raha | President and CEO | Award (A) | +3,542 | $3.94 | $13.9K | EDGAR |
| 2026-06-09 | Rashmi Kumar | Director | Sell (S) | −15,000 | $4.46 | -$66.8K | EDGAR |
| 2026-06-05 | Paul Bisaro | Director | Award (A) | +59,701 | — | EDGAR | |
| 2026-06-05 | Colleen F Reitan | Director | Award (A) | +59,701 | — | EDGAR | |
| 2026-06-05 | S. Louise Phanstiel | Director | Award (A) | +59,701 | — | EDGAR | |
| 2026-06-05 | Rashmi Kumar | Director | Award (A) | +59,701 | — | EDGAR | |
| 2026-06-05 | Mark Steven Davis | Director | Award (A) | +59,701 | — | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
MYGN Insider Holdings
22 insiders · @ $5.74
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Samraat S. Raha | President and CEO | 1,068,083 | $6.13M | $199.8K | 11 | 2026-06-12 |
| 2 | Paul J Diaz | President and CEO | 891,844 | $5.12M | -$6.47M | 22 | 2025-04-30 |
| 3 | Mark Verratti | Chief Operating Officer | 629,646 | $3.61M | $0 | 46 | 2026-04-15 |
| 4 | Brian J Donnelly | Chief Commercial Officer | 573,363 | $3.29M | $0 | 5 | 2026-09-18 |
| 5 | S. Louise Phanstiel | Director | 374,771 | $2.15M | -$1.15M | 22 | 2026-06-05 |
| 6 | Vishal Sikri | EVP, Commercial | 351,224 | $2.02M | $0 | 1 | 2026-09-17 |
| 7 | Jennifer Lynne Fox | Chief Legal & Corp Strategy | 345,334 | $1.98M | $0 | 6 | 2026-11-02 |
| 8 | Dale Muzzey | Chief Scientific Officer | 326,310 | $1.87M | -$55.0K | 26 | 2026-04-15 |
| 9 | Benjamin Richard Wheeler | Chief Financial Officer | 287,193 | $1.65M | $0 | 8 | 2026-09-22 |
| 10 | Shereen Solaiman | Chief People Officer | 273,585 | $1.57M | $0 | 7 | 2026-03-16 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
MYGN Board & Officers
As of SEC filings through Nov 2, 2026Directors 8
- S. Louise Phanstiel · since Sep 16, 2009
- Colleen F Reitan · since Sep 25, 2019
- Lee Nisley Newcomer · since Sep 25, 2019
- Rashmi Kumar · since Sep 10, 2020
- Heinrich Dreismann · on file since Jun 2022
- Paul Bisaro · since Oct 31, 2022
- Mark Steven Davis · since Dec 10, 2024
- Samraat S. Raha · listed since May 2025
Officers 8
- Samraat S. Raha · President and CEO · listed since May 2025
- Benjamin Richard Wheeler · Chief Financial Officer · since Aug 16, 2025
- Mark Verratti · Chief Operating Officer · listed since May 2025
- Dale Muzzey · Chief Scientific Officer · since Apr 14, 2022
- Shereen Solaiman · Chief People Officer · since Mar 1, 2023
- Jennifer Lynne Fox · Chief Legal Officer · since Sep 3, 2024
- Raj Jampa · Chief Technology Officer · since Jun 1, 2026
- Vishal Sikri · EVP, Commercial · since Sep 16, 2026
Changes in the last 10 years (59)
| Sep 16, 2026 | Vishal Sikri became EVP, Commercial |
| Sep 16, 2026 | Brian J Donnelly left as Chief Commerical Officer, per their own SEC filing |
| Jun 17, 2026 | Daniel Skovronsky left the board, per their own SEC filing |
| Jun 1, 2026 | Raj Jampa became Chief Technology Officer |
| Mar 16, 2026 | Kevin Richard Haas left as Chief Technology Officer, per their own SEC filing |
| Nov 3, 2025 | Margaret Ancona left as SVP, Chief of Staff, per their own SEC filing |
| Oct 24, 2025 | Natalie Munk left as Chief Accounting Officer, per their own SEC filing |
| Aug 16, 2025 | Benjamin Richard Wheeler became Chief Financial Officer |
| Aug 15, 2025 | Scott J. Leffler left as Chief Financial Officer, per their own SEC filing |
| May 1, 2025 | Samraat S. Raha listed as President and CEO (previously Chief Operating Officer) in SEC filings |
| May 1, 2025 | Samraat S. Raha first listed as a director in an SEC filing |
| May 1, 2025 | Mark Verratti listed as Chief Operating Officer (previously Chief Commercial Officer) in SEC filings |
| May 1, 2025 | Brian J Donnelly became Chief Commerical Officer |
| Apr 30, 2025 | Paul J Diaz left the board, per their own SEC filing |
| Apr 30, 2025 | Paul J Diaz left as President and CEO, per their own SEC filing |
| Dec 10, 2024 | Mark Steven Davis became a director |
| Sep 3, 2024 | Jennifer Lynne Fox became Chief Legal Officer |
| Jun 6, 2024 | Daniel K Spiegelman left the board, per their own SEC filing |
| Mar 22, 2024 | Pamela Wong left as Chief Legal Officer, per their own SEC filing |
| Jan 29, 2024 | Scott J. Leffler became Chief Financial Officer |
| Jan 29, 2024 | Richard Bryan Riggsbee left as Chief Financial Officer, per their own SEC filing |
| Dec 11, 2023 | Samraat S. Raha became Chief Operating Officer |
| Oct 31, 2023 | Nicole Lambert left as Chief Operating Officer, per their own SEC filing |
| Mar 1, 2023 | Shereen Solaiman became Chief People Officer |
| Mar 1, 2023 | Jayne B. Hart left as Chief People Officer, per their own SEC filing |
| Feb 27, 2023 | Margaret Ancona listed as SVP, Chief of Staff (previously SVP Enterprise Transformation) in SEC filings |
| Oct 31, 2022 | Paul Bisaro became a director |
| Jun 30, 2022 | Dennis Langer left the board, per their own SEC filing |
| Jun 3, 2022 | Heinrich Dreismann first on file as a director |
| Jun 2, 2022 | Natalie Munk became Chief Accounting Officer |
| Apr 26, 2022 | Eric Santa left as Chief Growth Officer, per their own SEC filing |
| Apr 14, 2022 | Mark Verratti listed as Chief Commercial Officer (previously President, Mental Health) in SEC filings |
| Apr 14, 2022 | Dale Muzzey became Chief Scientific Officer |
| Feb 18, 2022 | Nicole Lambert listed as Chief Operating Officer (previously President, MGL) in SEC filings |
| Feb 18, 2022 | Mark Verratti listed as President, Mental Health (previously President, Myriad Neuroscience) in SEC filings |
| Jan 14, 2022 | Jerry S Lanchbury left as Chief Scientific Officer, per their own SEC filing |
| Oct 18, 2021 | Pamela Wong became Chief Legal Officer |
| May 14, 2021 | Paul Parkinson left as EVP Strategy and Innovation, per their own SEC filing |
| Apr 12, 2021 | Benjamin Jackson left as E.V.P., General Counsel, per their own SEC filing |
| Apr 1, 2021 | Eric Santa became Chief Growth Officer |
| Mar 26, 2021 | Mark Verratti listed as President, Myriad Neuroscience (previously President Assurex Health Inc.) in SEC filings |
| Mar 26, 2021 | Kevin Richard Haas listed as Chief Technology Officer (previously SVP Technology) in SEC filings |
| Mar 26, 2021 | Jayne B. Hart listed as Chief People Officer (previously Executive VP Human Resources) in SEC filings |
| Feb 18, 2021 | Margaret Ancona became SVP Enterprise Transformation |
| Feb 18, 2021 | Kevin Richard Haas became SVP Technology |
| Sep 24, 2020 | Paul Parkinson became EVP Strategy and Innovation |
| Sep 16, 2020 | Alexander Ford listed as Chief Operating Officer (previously President, MWH) in SEC filings |
| Sep 10, 2020 | Rashmi Kumar became a director |
| Aug 13, 2020 | Paul J Diaz became a director |
| Aug 13, 2020 | Paul J Diaz became President and CEO |
| Jul 21, 2020 | Daniel Skovronsky became a director |
| May 27, 2020 | Daniel K Spiegelman became a director |
| Sep 26, 2019 | Alexander Ford listed as President, MWH (previously President, MGL) in SEC filings |
| Sep 25, 2019 | Lee Nisley Newcomer became a director |
| Sep 25, 2019 | Colleen F Reitan became a director |
| Jul 1, 2019 | Benjamin Jackson became E.V.P., General Counsel |
| Apr 1, 2019 | Nicole Lambert became President, MGL |
| Aug 1, 2018 | Walter Lloyd Sanders became President Myriad Oncology |
| Aug 1, 2017 | Mark Verratti became President Assurex Health Inc. |
Not reported recently (11)
- Heinrich Dreismann · Last reported as a director in an SEC filing dated Jun 4, 2021
- Alexander Ford · Last reported as Chief Operating Officer in an SEC filing dated Oct 1, 2020
- Walter Phd Gilbert · Last reported as a director in an SEC filing dated Dec 16, 2019
- John T Henderson · Last reported as a director in an SEC filing dated Dec 6, 2019
- Lawrence C Best · Last reported as a director in an SEC filing dated Dec 6, 2019
- Mark Christopher Capone · Last reported as President & C.E.O. in an SEC filing dated Oct 1, 2019
- Gary A. King · Last reported as Exec. VP International Ops in an SEC filing dated Oct 1, 2019
- Ralph L McDade · Last reported as President Myriad RBM, Inc. in an SEC filing dated Oct 1, 2019
- Bernard Tobin · Last reported as President Crescendo BioScience in an SEC filing dated Oct 1, 2019
- Richard M Marsh · Last reported as E.V.P., General Counsel in an SEC filing dated Oct 2, 2018
- Walter Lloyd Sanders · Last reported as President Myriad Oncology in an SEC filing dated Oct 2, 2018
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
MYGN Proposed Insider Sales (Form 144)
Latest: 2026-06-08
? Form 144 Guide
Last 30d:
0 filings
· Last 90d:
0 filings
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-06-08 | Kumar Rashmi | Director | 15,000 | $68.8K | 2026-06-08 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
| 2024-10-11 | DIAZ PAUL J | Officer, Director | 15,000 | $343.9K | 2024-10-11 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
| 2024-09-16 | Ancona Margaret | Officer | 11,538 | $321.0K | 2024-08-21 | Merrill Lynch | — | EDGAR |
| 2024-09-11 | Muzzey Dale | Officer | 2,100 | $55.0K | 2024-09-11 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2024-09-11 | DIAZ PAUL J | Officer, Director | 15,000 | $400.8K | 2024-09-11 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
| 2024-09-09 | Dreismann Heinrich | Director | 10,000 | $270.0K | 2024-09-10 | Merrill Lynch | 10b5-1 | EDGAR |
| 2024-09-03 | Reitan Colleen F | Director | 46,012 | $1.30M | 2024-09-03 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
| 2024-08-19 | Kumar Rashmi | Director | 7,500 | $210.1K | 2024-08-19 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
| 2024-06-04 | SPIEGELMAN DANIEL K | Director | 3,788 | $83.5K | 2024-06-04 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
| 2024-06-03 | SPIEGELMAN DANIEL K | Director | 3,788 | $83.5K | 2024-06-03 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
Recent SEC Filings
Latest: 2026-11-06
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
| Filing Date | Event | Link |
|---|---|---|
| 2026-11-05 | Other events | EDGAR |
| 2026-11-04 | Earnings results | EDGAR |
| 2026-10-20 | Material agreement · Regulation FD disclosure | EDGAR |
| 2026-10-09 | Director or officer change | EDGAR |
| 2026-09-16 | Director or officer change · Regulation FD disclosure | EDGAR |
| 2026-07-30 | Earnings results | EDGAR |
| 2026-06-23 | Director or officer change | EDGAR |
| 2026-06-04 | Director or officer change · Shareholder vote results | EDGAR |
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
| Filing Date | Accession | Link |
|---|
ETF Holders
53 ETFs hold MYGN
25 shown · $81.14M total exposure · 0.02% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | XBI State Street® SPDR® S&P® Biotech ETF | SPDR (State Street) | 0.18% | $18.4M | $10.0B | 2026-11-05 |
| 2 | IWM iShares Russell 2000 ETF | iShares (BlackRock) | 0.02% | $14.3M | $76.6B | 2026-11-06 |
| 3 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.00% | $12.4M | — | 2026-09-30 |
| 4 | IWN iShares Russell 2000 Value ETF | iShares (BlackRock) | 0.04% | $5.2M | $13.9B | 2026-11-06 |
| 5 | FESM Fidelity Enhanced Small Cap Core ETF | Fidelity | 0.07% | $4.5M | $6.6B | 2026-11-05 |
| 6 | VXF Vanguard Extended Market ETF | Vanguard | 0.00% | $4.4M | — | 2026-09-30 |
| 7 | IBB iShares Biotechnology ETF | iShares (BlackRock) | 0.04% | $4.0M | $11.1B | 2026-11-06 |
| 8 | VTWO Vanguard Russell 2000 ETF | Vanguard | 0.01% | $2.3M | — | 2026-09-30 |
| 9 | FNDA Schwab Fundamental U.S. Small Company ETF | Nport | 0.02% | $1.4M | — | 2026-08-31 |
| 10 | SCHA Schwab U.S. Small-Cap ETF | Nport | 0.01% | $1.4M | — | 2026-08-31 |
| 11 | AVUV Avantis U.S. Small Cap Value ETF | Avantis | 0.00% | $1.4M | $31.6B | 2026-11-05 |
| 12 | VHT Vanguard Health Care ETF | Vanguard | 0.01% | $1.2M | — | 2026-09-30 |
| 13 | SMLF iShares U.S. Small-Cap Equity Factor ETF | iShares (BlackRock) | 0.03% | $1.2M | $4.2B | 2026-11-06 |
| 14 | DFAS Dimensional US Small Cap ETF | Dimensional | 0.00% | $1.1M | — | 2026-11-05 |
| 15 | VFVA Vanguard U.S. Value Factor ETF | Vanguard | 0.11% | $1.0M | — | 2026-11-05 |
| 16 | GSSC Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF | Goldman | 0.10% | $1.0M | $1.0B | 2026-11-05 |
| 17 | DFMC Dimensional US Micro Cap ETF | Dimensional | 0.01% | $1.0M | — | 2026-11-05 |
| 18 | ITOT iShares Core S&P Total U.S. Stock Market ETF | iShares (BlackRock) | 0.00% | $749,194 | $93.2B | 2026-11-06 |
| 19 | LABU Direxion Daily S&P Biotech Bull 3X ETF | Direxion | 0.13% | $663,771 | — | 2026-11-06 |
| 20 | AVSC Avantis U.S. Small Cap Equity ETF | Avantis | 0.02% | $662,048 | $3.2B | 2026-11-05 |
| 21 | FSCC Federated Hermes MDT Small Cap Core ETF | Nport | 0.17% | $619,976 | — | 2026-08-31 |
| 22 | SMIZ Zacks Small/Mid Cap ETF | Nport | 0.20% | $548,627 | — | 2026-08-31 |
| 23 | VFQY Vanguard U.S. Quality Factor ETF | Vanguard | 0.11% | $537,952 | — | 2026-11-05 |
| 24 | PRFZ Invesco RAFI US 1500 Small-Mid ETF | Nport | 0.02% | $499,004 | — | 2026-07-31 |
| 25 | DFAC Dimensional US Core Equity 2 ETF | Dimensional | 0.00% | $430,249 | — | 2026-11-05 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
$-1.18
TTM Revenue
$806.60M
TTM Net Income
$-112.60M
TTM Op. Cash Flow
$7.70M
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q2 '26 | 2026-06-30 | $190.70M | $-43.20M | $-0.46 | $-8.30M |
| Q1 '26 | 2026-03-31 | $200.40M | $-34.10M | $-0.36 | $-15.70M |
| Q4 '25 | 2025-12-31 | $209.80M | $-7.90M | $-0.07 | $10.60M |
| Q3 '25 | 2025-09-30 | $205.70M | $-27.40M | $-0.29 | $21.10M |
| Q2 '25 | 2025-06-30 | $213.10M | $-330.50M | $-3.57 | $-13.60M |
| Q1 '25 | 2025-03-31 | $195.90M | $-100.00K | — | $-16.30M |
| Q4 '24 | 2024-12-31 | $210.60M | $-42.50M | $-0.47 | $6.60M |
| Q3 '24 | 2024-09-30 | $213.30M | $-22.10M | $-0.24 | $700.00K |
| Q2 '24 | 2024-06-30 | $211.50M | $-36.70M | $-0.41 | $2.60M |
| Q1 '24 | 2024-03-31 | $202.20M | $-26.00M | $-0.29 | $-18.60M |
| Q4 '23 | 2023-12-31 | $196.60M | $-31.20M | $-0.34 | $-54.70M |
| Q3 '23 | 2023-09-30 | $191.90M | $-61.30M | $-0.75 | $-22.10M |
Q2 2026 • period ending 2026-06-30 • filed 2026-07-31
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
1.77
P/S
0.67
EV/EBITDA
—
EV/Sales
0.68
ROE
-37.1%
ROA
-17.6%
Div Yield
0.00%
FCF Yield
1.43%
Debt/Equity
0.40
Current Ratio
—
Market Cap
$539.32M
as of 2026-11-09
MYGN vs Peers
Related companies, largest first| Company | Market cap | P/E | Revenue growth | YTD | IV rank |
|---|---|---|---|---|---|
| VRTX Vertex Pharmaceuticals Inc | $138.7B | 35.4 | +10.5% | +21.8% | 60 |
| MRNA Moderna, Inc. Common Stock | $101.5B | — | −27.6% | +797.9% | 51 |
| GH Guardant Health, Inc. Common Stock | $20.4B | — | +42.7% | +58.4% | 25 |
| TECH Bio-Techne Corp. | $11.4B | 63.4 | −0.4% | +22.1% | 36 |
| BMRN BioMarin Pharmaceuticals Inc | $10.9B | — | +18.1% | −3.8% | 31 |
| QGEN QIAGEN N.V. | $10.4B | — | — | +12.0% | 14 |
| TWST Twist Bioscience Corporation Common Stoc | $8.0B | — | +17.8% | +324.4% | 95 |
| CDNA CareDx, Inc. | $4.1B | 35.5 | +38.9% | +343.6% | 36 |
| MYGN Myriad Genetics Inc | $564M | — | −3.2% | −6.5% | 38 |
| Peer median | $11.1B | 35.5 | +17.8% | +40.3% | 36 |
P/E uses the latest reported trailing-12-month diluted EPS; "—" means no positive earnings or no data.
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
9.27M
SI % of Float
10.07%
Days to Cover
5.32
Short Vol Ratio
45.6%
Free Float
92.05M
Float %
96.2%
Short interest 2026-10-15 • Short volume 2026-11-06 • Float 2026-08-14